Neuroprotection in emerging psychotic disorders
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Aim: The emerging phase of psychotic disorders is pleomorphic and fluctuates in presentation. Hence, from a clinical perspective, treatment modalities are often unclear. This paper investigates the rational and potential use of neuroprotective agents in emerging psychotic disorders. Methods: Medline databases were searched from 1966 to 2006 followed by the cross‐checking of references using following keywords: neuroprotection, apoptosis, natural cell death, neurodevelopment, plasticity, neurogenesis, combined with brain and schizophrenia. Results: Agents such as atypical antipsychotics, antidepressants, omega‐3 fatty acids, modulators of glutamateric neurotransmission (e.g. ampakines, glycine, memantine), erythropoietin,N‐acetylcysteine, COX‐2 inhibitors or antioxidants have neuroprotective (anti‐apoptotic) properties and may therefore be able to protect brain maturational processes disturbed in emerging psychotic disorders. Clinical trials suggest that atypical antipsychotics, antidepressants, omega‐3 fatty acids and low‐dose lithium as sole treatments were able to improve symptoms and functioning, and delay or in some cases even prevent the onset of frank psychosis. Initially these substances have been chosen because they have been used either as sole or augmentation treatments in established psychotic disorders. However, chronicity and already effective treatments may overshadow their potential clinical use in emerging (prodromal) psychosis. Conclusion: Neuroprotection as a new treatment paradigm for at‐risk mental states seems to be promising and pilot data are suggestive that more benign interventions may already be sufficient to delay or even prevent the onset of frank psychosis. A coordinated research effort will be necessary to address the question which agents should be used under which circumstances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
Functional neurogenesis in the adult hippocampus
van Praag, H., Schinder, A. F., Christie, B. R., Toni, N., Palmer, T. D., & Gage, F. H. (2002) · Nature · doi:10.1038/4151030a · Cited by 2,853
Astroglia induce neurogenesis from adult neural stem cells
Song, H., Stevens, C. F., & Gage, F. H. (2002) · Nature · doi:10.1038/417039a · Cited by 1,452
Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?
Feinberg, I. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90038-3 · Cited by 1,395
The Prodromal Phase of First-episode Psychosis: Past and Current Conceptualizations
Yung, A. R., & McGorry, P. D. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.2.353 · Cited by 1,168
Self-citationIncreased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication
Chen, B., Dowlatshahi, D., MacQueen, G. M., Wang, J.-F., & Young, L. T. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01083-6 · Cited by 1,164
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group
Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S. M., McFarlane, C. A., Hallgren, M., & McGorry, P. D. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00167-6 · Cited by 1,136
Self-citationMcGorry, P. D., Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S., Cosgrave, E. M., Germano, D., Bravin, J., McDonald, T., Blair, A., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.921 · Cited by 1,056 · cited 1×
“The few clinical studies are suggestive that we can at least delay the progression to frank psychosis in some cases from a clinical perspective.(7,8,69)”
BackgroundSelf-citationDiagnosing schizophrenia in the initial prodromal phase
Klosterkötter, J., Hellmich, M., Steinmeyer, E. M., & Schultze-Lutter, F. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.2.158 · Cited by 1,049
Cited by
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Self-citationEarly intervention in psychosis: concepts, evidence and future directions
MCGORRY, P. D., KILLACKEY, E., & YUNG, A. (2008) · World Psychiatry · doi:10.1002/j.2051-5545.2008.tb00182.x · Cited by 581
“A second generation of single site clinical trials has recently been completed, with interesting results for a range of psychosocial and biological therapies, including cognitive therapy (62), lithium (63), omega-3 fatty acids (64), and atypical antipsychotics (60).”
BackgroundSelf-citationIntervention in Individuals at Ultra-High Risk for Psychosis: A Review and Future Directions
McGorry, P. D., Nelson, B., Amminger, G. P., Bechdolf, A., Francey, S. M., Berger, G., Riecher-Rössler, A., Klosterkötter, J., Ruhrmann, S., Schultze-Lutter, F., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04472 · Cited by 305
Self-citationMcGorry, P. D., Nelson, B., Goldstone, S., & Yung, A. R. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500803 · Cited by 279
Self-citation
Metadata
- Authors
- Berger, G., Dell’Olio, M., Amminger, P., Cornblatt, B., Phillips, L., Yung, A., Yan, Y., Berk, M., & McGorry, P.
- Venue
- Early Intervention in Psychiatry
- Publisher
- Wiley
- Published
- 2007-05
- Volume
- 1
- Issue
- 2
- Pages
- 114-127
- ISSN
- 1751-7885 (ISSN-L)
- 1751-7893
- OpenAlex
- W1967224402
- Cited by
- 79
- References
- 25
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotection in emerging psychotic disorders. https://app.cochat.ai/papers/10.1111/j.1751-7893.2007.00021.x
- The paper
- Berger, G., Dell’Olio, M., Amminger, P., Cornblatt, B., Phillips, L., Yung, A., Yan, Y., Berk, M., & McGorry, P. (2007). Neuroprotection in emerging psychotic disorders. Early Intervention in Psychiatry. https://doi.org/10.1111/j.1751-7893.2007.00021.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.